At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 491 enrolled
Drug / intervention
nebivolol +1 moredrug
Likely dose
nebivolol 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Nebivolol Added To Antihypertensive Treatment With Lisinopril or Losartan in Patients With Hypertension.
In Brief
A Phase 4 clinical trial evaluating nebivolol and Placebo for Hypertension. Completed, enrolled 491 participants across 75 sites.
Detailed Summary
This study will assess blood pressure reduction with nebivolol or placebo in patients taking lisinopril or losartan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedAug 2008
Primary CompletionMar 2010
Study CompletionMay 2010
TodayJul 2026
First PostedAug 14, 2008
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2010
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.9 years ago
Interventions
nebivololdrug
Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
Placebodrug
Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration